Paul Conkling, MD
Hematology-Oncology · Norfolk, VANPI 1063417806
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,170 of the $3,510 with a category attached, or 90.3%. F. Hoffmann-la Roche AG accounts for 69.7% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $2,459 and has fallen 96.3% since, to $92 in 2025.
Across 11 payments — averaging $319.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$2K
- Boehringer Ingelheim$723
- Sobi, Inc$125
- Sanofi-aventis U.S. LLC$99
- Daiichi Sankyo Inc.$92
- Seagen Inc.$12
- plus $12 from 1 others
Across 166 payments — averaging $3694.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$272K
- Genentech, Inc.$142K
- Pfizer$70K
- EMD Serono, Inc.$51K
- AstraZeneca$36K
- Roche Products Limited$25K
- plus $18K from 4 others
What the payments were for
- Speaking & faculty fees$3,17090%
- Food & beverage$2176%
- Education$1234%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 4 | $2,447 |
| Boehringer Ingelheim | 2 | $723 |
| Sobi, Inc | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Daiichi Sankyo Inc. | 1 | $92 |
| Seagen Inc. | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$2,447
- DOPTELET$125
How this compares
Too few hematology-oncology providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in Norfolk
- Edward GeorgeNorfolk$323K
- Burton AlexanderNorfolk$612
- Michael LeeNorfolk$501
- Scott CrossNorfolk$388
- Ravneet GrewalLansdowne$10K
- John PascholdWilliamsburg$6K
- Valiant TanChesapeake$3K
- David PowellHampton$610
- John KesslerNewport News$194
- Kathryn CappellFairfax$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.